Sign in
Taking people in FranceNo phase

Virtual reality to ease ongoing breathlessness in people with ALS on breathing support

Tests immersive virtual reality for ongoing breathlessness in adults with ALS using breathing support.

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
Paris, FranceSee the site
Trial code
Registry title
Alleviating Persistent Dyspnea in Amyotrophic Lateral Sclerosis Patients Treated With Non-Invasive Ventilation Through Immersive Virtual Reality
Status
Recruiting
People taking part
35 people, planned
Started
4 Apr 2024
Expected to end
4 Apr 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Immersive virtual reality (IVR) & Music therapy
Record updated
25 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with ALS who still feel short of breath although they use non-invasive ventilation (NIV).

Age
18 years or older
Sex
Women and men can join
Disease stage
ALS confirmed by the revised El Escorial criteria. Breathing failure from a weak diaphragm. Shortness of breath at rest scored 3 or more on a 0 to 10 scale, in a semi-sitting position. Stable condition, with no hospital stay for acute heart, breathing or nerve failure in the last 4 weeks.
Earlier treatment
Must have used non-invasive ventilation for more than a month. Care is given in an ambulatory setting (day care hospital).

Main reasons for not taking part

  • Brain or nerve disorders such as dementia, brain tumor, stroke or Parkinson's disease
  • Diagnosed psychiatric illness, or taking antipsychotic treatment
  • Fear of heights, closed spaces or light (acrophobia, claustrophobia, photophobia)
  • Hearing loss or visual impairment
  • Under guardianship or curatorship

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • ≥ 18 years old
  • Diagnosis of ALS confirmed according to the revised criteria of El Escorial
  • Respiratory failure due to diaphragmatic dysfunction treated by non-invasive ventilation for more than a month
  • Care provided in an ambulatory setting (day care hospital)
  • Persistent dyspnea at rest ≥ 3 across a numerical scale (0 to 10) in a semi-sitting position
  • Stable clinical condition, i.e., no episode of acute cardiac, respiratory and/or neurological failure leading to hospitalization in the previous 4 weeks
  • Free, prior and informed written consent about the study has been obtained
  • Benefiting a social security (French health insurance system)

Who cannot take part

  • Diagnosed psychiatric illness (severe depression, psychosis) or receiving antipsychotic treatment
  • Neurological disorders according to a neurological evaluation dating from less than one year, in particular diagnosed dementia (frontotemporal dementia, Alzheimer's disease, etc.), brain pathology (tumor, stroke, Parkinson's disease, etc.)
  • Visual impairment
  • Acrophobia
  • Claustrophobia
  • Photophobia
  • Hearing loss
  • Subject under guardianship or curatorship

Where in France

  • Service de PneumologieParis, FranceContact: Capucine MORELOT PANZINITaking people

About the trial

What the trial wants to find out

The evolution of amyotrophic lateral sclerosis (ALS) is marked by dyspnea, anxiety and pain, major determinants of suffering induced by this disease. The only palliative treatment for respiratory failure is non-invasive ventilation (NIV), which compensates failing respiratory muscles and relieves dyspnea, improves quality of life and increases life expectancy. In ALS patients, the persistence of dyspnea outside of NIV sessions has highlighted the need for therapeutic alternatives in the treatment of persistent dyspnea, including immersive virtual reality (IVR) and auditory distraction through music (music therapy). This study evaluates the effect of IVR on respiratory discomfort in ALS patients with persistent dyspnea treated with NIV.

The 2 groups in the trial

  • Patients starting with RVIExisting treatment, for comparison

    Patients will begin by wear a virtual reality headset (GAMIDA®) and headphones (Bose®). A tablet (Samsung®) equipped with "Healthy Mind" software will allow patients to live a 360° visual and auditory 3D experience via Bluetooth connection. After that patients will be handed a smartphone with the Spotify® application to listen to music. Patients will wear headphones.

    Treatment: Immersive virtual reality (IVR) & Music therapy

  • Patients starting with music therapyExisting treatment, for comparison

    Patients will begin by handed a smartphone with the Spotify® application to listen to music. Patients will wear headphones. After that patients will wear a virtual reality headset (GAMIDA®) and headphones (Bose®). A tablet (Samsung®) equipped with "Healthy Mind" software will allow patients to live a 360° visual and auditory 3D experience via Bluetooth connection.

    Treatment: Immersive virtual reality (IVR) & Music therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Alleviating Persistent Dyspnea in Amyotrophic Lateral Sclerosis Patients Treated With Non-Invasive Ventilation Through Immersive Virtual Reality
Plain-language title
Virtual reality to ease ongoing breathlessness in people with ALS on breathing supportGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
25 February 2026